ARGX — ARGENX SE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1697862 ·
Belgium
Last close
$958.91
Market Cap
$59.63B
52W High
$1072.75
52W Low
$661.85
ADV30
258,231
Next earnings
2026-10-22
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,515,000,000 | 1,370,000,000 | 494,000,000 | 472,000,000 | 10,032,000,000 | 3,584,000,000 | 1,615,000,000 |
| Mar 2026 | 1,298,000,000 | 1,177,000,000 | 394,000,000 | 366,000,000 | — | — | — |
| Dec 2025 | 1,287,877,000 | 1,138,190,000 | 359,557,000 | 532,950,000 | 8,682,698,000 | 3,491,289,000 | 1,359,606,000 |
| Sep 2025 | 1,126,961,000 | 1,017,535,000 | 349,970,000 | 344,258,000 | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$558,000,000
Inventory
$371,000,000
Receivables
$1,941,000,000
ST Investments
$1,600,000,000
EBIT TTM
$1,751,168,000
Pretax Income TTM
$1,747,347,000
Interest Exp TTM
$3,821,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,315,468,800
EBITDA
$1,612,902,016
Free Cash Flow
$761,769,024
Enterprise Value
$1,533,905,600,512
Total Cash
$5,184,000,000
Total Debt
$47,000,000
Shares Out
62,187,771
Trailing EPS
$26.21
Book Value
$5.38
ROE
23.6%
ROA
11.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,153,482,000 | 1,054,615,000 | 1,292,035,000 | 8,682,698,000 | 1,359,606,000 | 7,323,092,000 | 685,192,000 |
| Dec 2024 | 2,190,231,000 | -17,844,000 | 833,040,000 | 6,202,522,000 | 704,239,000 | 5,498,283,000 | -82,747,000 |
| Dec 2023 | 1,226,316,000 | -420,638,000 | -295,053,000 | 4,542,458,000 | 444,951,000 | 4,097,507,000 | -420,327,000 |
| Dec 2022 | 410,746,000 | -723,919,000 | -709,594,000 | 3,134,261,000 | 320,562,000 | 2,813,699,000 | -862,807,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$34.51
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $840.00 · spot: $958.91 · call volume: 506 · put volume: 355
Expected Move to 2026-12-18:
±$141.70
(14.78%) —
implied range
$817.21 –
$1100.61
· ATM straddle on $960.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRNA | Moderna, Inc. | $76.88B | $192.57 | — |
| RVMD | Revolution Medicines, Inc. | $43.99B | $205.26 | — |
| BIIB | BIOGEN INC. | $33.37B | $225.88 | — |
| BNTX | BioNTech SE | $24.69B | $98.30 | — |
| GILD | GILEAD SCIENCES, INC. | $184.82B | $149.05 | — |
News headlines (Yahoo Finance, 1h cache)
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
2026-09-29 12:00 · Yahoo
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months
2026-09-26 09:04 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Lower in Thursday Trading
2026-09-24 15:10 · Yahoo
argenx (ENXTBR:ARGX) Stock Could Be Pricey Despite Strong Earnings Expectations
2026-09-24 03:22 · Yahoo
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.
2026-09-20 10:12 · Yahoo
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
2026-09-17 20:03 · Yahoo
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
2026-09-02 12:00 · Yahoo
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
2026-09-02 09:04 · Yahoo
argenx to Present at Upcoming Investor Conferences
2026-09-01 05:00 · Yahoo
A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
2026-08-28 13:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.